vorasidenib
servier
['vorasidenib']
amazing news at #asco2023. #vorasidenib for idh mutant low grade glioma. progression free survival 27.7 months vs. 11.1 months on placebo. this is fuel to continue working towards better treatments and one day #endbraincancer. 
Neuro-oncologist, Neuroimmunologist
Interim Director, Neuro-oncology 
Perlmutter Cancer Center at NYU Langone Health
@Perlmutter_CC